AndhraNews.net
Home » Features » Health » Diabetes

Diabetes


Diabetes

About Diabetes

Diabetes is a polygenic disease characterized by abnormally high glucose levels in the blood; any of several metabolic disorders marked by excessive urination.

Identifying a master regulator gene for early embryonic development of the pancreas and other organs, scientists at Cincinnati Childrens Hospital Medical Center have moved a step closer to coaxing stem cells into pancreatic cells as a possible cure for type1 diabetes.

A commonly prescribed anti-diabetic drug can reduce an individuals risk of developing pancreatic cancer by 62 percent, according to a study.

A gene previously shown to be involved in the development of type 2 diabetes also predisposes children to having a lower birth weight, according to a study.

Low levels of Vitamin D are associated with diabetes.

Type 2 Diabetes

Research revealed that Type 2 Diabetes can be cured by consuming a low-calorie diet daily for four months. The study showed that people who cut down on their calories intake had a significant improvement in the condition.

Diabetes Studies and Research

In May 2012, a new study has revealed that a potent two-pronged attack on diabetes can cure it. The powerful combination therapy can tackle the condition even at a late stage.

Facts

  • As of 2012, around 370,000 Britons have Type 1 diabetes.

Diabetes in News

​Dr. Gregory Brammer -- Discusses Workplace Violence in the Emergency Department
NEW YORK, NY--(Marketwired - December 30, 2015) - Gregory Brammer, Expert Emergency Medicine Specialist and Fellow of the American College of Emergency Physicians, has recently brought awareness to the massive systemic problem of workplace violence in our nation's Emergency Departments (ED)

Full Tummy Tuck vs. Mini Tummy Tuck -- What's the Difference?
A tummy tuck, or "abdominoplasty," is one of the most commonly requested cosmetic surgery procedures today. After all, who would say no to a slimmer, flatter stomach? Tummy tucks help streamline the shape and do wonders for self-esteem. Dr

Orgenesis Note Holders Elect to Convert $950,000 of Outstanding Notes
Orgenesis Inc

Boston Therapeutics' sugardown(R) in Clinical Trials Reduces Glucose, Fructose and Insulin
Boston Therapeutics, Inc. (OTCQB: BTHE) released final trial results from its proof of concept (POC) Sydney University study that showed consumption of sugardown® tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a favorable response

Dr. Gregory Brammer -- Supports Expanded Point-of-Care Testing in the Pre-Hospital Arena
NEW YORK, NY--(Marketwired - December 23, 2015) - Renowned Emergency Medicine Expert Physician Dr. Gregory Brammer has voiced his opinion regarding Point-of-Care-Testing (POCT) and the 2014 EMSWORLD article entitled "WHAT'S THE POINT of Point-of-Care Testing", where the vast potential of POCT was extolled

Liberator Medical Announces Definitive Settlement of Qui Tam Litigation
STUART, FL--(Marketwired - December 22, 2015) - Liberator Medical Holdings, Inc. ("Liberator") (NYSE MKT: LBMH), a leading national direct-to-consumer provider of quality medical supplies through its subsidiary, Liberator Medical Supply, Inc., today announced that it has entered into a definitive settlement with the U.S

Flamel Technologies Announces Positive Interim Results of a First-in-Man Clinical Trial With Medusa(TM) Exenatide
Flamel Technologies (NASDAQ: FLML) today announced positive interim results from a Phase 1a clinical trial in healthy volunteers of a once weekly subcutaneous injection formulation of exenatide using its proprietary Medusa™ technology (FT228). The study achieved all safety and pharmacokinetic (PK) assessment objectives throughout ascending single dose administrations of FT228

Zivo Bioscience Subsidiary, WellMetris LLC, Concludes Production Run of Human Wellness Testing Assays, Begins Validation
ZIVO Bioscience, Inc. (OTCQB: ZIVO), announces today that its wholly-owned subsidiary, WellMetris LLC, has successfully concluded manufacturing runs of assays for its proprietary, patent-pending metabolic testing panel for human application. The manufacturing run completes the full wellness panel with the latest assay formulations.

Biodel Reports Fourth Quarter and Fiscal Year 2015 Financial Results
DANBURY, CT--(Marketwired - December 17, 2015) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the fourth fiscal quarter and year-ended September 30, 2015

Novo Nordisk successfully completes fourth phase 3a trial with semaglutide in people with type 2 diabetes
Bagsværd, Denmark, 17 December 2015 - Novo Nordisk today announced the headline results from the fourth phase 3a trial for semaglutide, SUSTAIN2. Semaglutide is a new GLP-1 analogue administered subcutaneously once weekly. The double-blinded trial investigated the efficacy and safety of 0.5 mg and 1

Dr. Gregory Brammer -- Brings Awareness to the New Diabetes Drug INVOKANA
NEW YORK, NY--(Marketwired - December 16, 2015) - Expert Emergency Medicine Specialist and Fellow of the American College of Emergency Physicians, Dr. Gregory Brammer has recently brought awareness to the potential dangers of the new diabetes drug INVOKANA (canagliflozin)

Bio-Rad Receives FDA Clearance for Its D-100 System for A1c Testing
HERCULES, CA--(Marketwired - December 16, 2015) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced that its D-100™ System for A1c testing has obtained clearance from the U.S

Orgenesis Secures $10 Million in Financing and Retains Ownership of MaSTherCell SA
Orgenesis Inc

L-Arginine -- A Good Tool in the Fight to Prevent Stroke
AMERICAN FORK, UT--(Marketwired - December 15, 2015) - Numerous studies indicate that the ingredients in the popular health supplement L-arginine Plus® may contribute to the prevention of stroke among adults. It may also play a role in the reduction of cholesterol levels, and the improvement of blood pressure, both of which contribute to helping combat heart disease.

Give the Gift of Sight
(Family Features) This holiday, give a gift that changes the way someone you care about sees the world -- a gift that keeps giving even after the holidays are over.

Solera Health Partners With Blue Mesa Health to Deliver Innovative Digital Program for Diabetes Prevention
Solera Health, Inc., a technology-enabled health community integrator for evidence-based chronic disease prevention, today announced that it has partnered with Blue Mesa Health, a digital therapeutics platform for chronic disease prevention, to deliver an innovative new digital National Diabetes Prevention Program (DPP) to help combat the diabetes epidemic

Iran's Pharmaceutical Sector to Become a Pharma Powerhouse Post Sanction Era - Biotechnology Sector to Have Lucrative Opportunities
Business Wire IndiaWith annual consumption of 30 billion units of various generic medicines, Iran, the second-biggest consumer of generics in the Asian continent spent over USD 4.5 billion on drugs in 2015

Biocon Introduces CIMIVIR-L™ for Hepatitis-C in India
Business Wire IndiaBiocon Ltd, Asia's premier biotechnology company, today announced the introduction of an advanced novel therapy CIMIVIR-L™ for the treatment of Hepatitis C in India. CIMIVIR-L™ is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is an equivalent of  the innovator product commercialized by Gilead Sciences in the US

Award Winning Leader and Author Dr Prem Publishes Guides to Medical Tourism and Wellness Tourism
Business Wire IndiaRising global health awareness with people seeking better and convenient avenues of healthcare and wellness has led to the creation of niche wellness and medical tourism sectors, two flourishing domains in the global tourism industry

Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
Business Wire IndiaSanofi and Boehringer Ingelheim today announced that the companies have entered into exclusive negotiations to swap businesses. The proposed transaction would consist of an exchange of Sanofi animal health business (“Merial”) with an enterprise value of €11

Cell MedX Corp. (CMXC) Announces Change of Auditors
Cell MedX Corp. (OTCBB: CMXC), (the "Company") announces that the Company has appointed Dale Matheson Carr-Hilton LaBonte LLP Chartered Accountants as its new independent auditors replacing Sadler, Gibb & Associates, LLC

Novo Nordisk receives FDA approval for Saxenda® for the treatment of obesity
Bagsværd, Denmark, 23 December 2014 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity

South Dakota Based Mitogenetics Revolutionizes How People Manage Diseases
Mitogenetics, a biomedical technology firm with strong South Dakota roots, in partnership with the State University of New York, is developing technology to regulate the action of mitochondria

Mitogenetics Revolutionizes How People Manage Diseases
Mitogenetics, a biomedical technology firm in partnership with the State University of New York, is developing technology to regulate the action of mitochondria

Stevia Corp. Confirms Protocol to Produce Synthetic CBD
Stevia Corp

Cell MedX Corp. (CMXC) Announces the First Order Received by Its Newly Formed Wholly Owned Subsidiary
Cell MedX Corp. (OTCBB: CMXC) (the "Company") is pleased to announce the formation of its wholly owned subsidiary, Avyonce Cosmedics Inc. ("Avyonce"). Avyonce will concentrate its efforts on the resale and marketing of spa technology and equipment to the worldwide beauty and wellness industry. Avyonce has received its first order for approximately US$55,000 from Dubai, United Arab Emirates.

Biodel Reports Fourth Quarter Fiscal Year 2014 Financial Results
DANBURY, CT--(Marketwired - December 17, 2014) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the fourth fiscal quarter ended September 30, 2014.

Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000
Addex Therapeutics /Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

ETST, an Emerging Health and Wellness Company, Adds Attorney, Steven Warm, Esq., to the Advisory Board to Assist With Its New Cutting Edge Nutritional Products, Dietary Supplements and All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil Products
BOCA RATON, FL--(Marketwired - December 16, 2014) - Earth Science Tech, Inc. (OTCQB: ETST) ("ETST" or "the Company"), a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, today announced the addition of Steven Warm, Esq. to its advisory board.

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Novartis International AG /Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Liberator Medical Reports Revenue of $74.5 Million for Its Fiscal Year Ended September 30, 2014
STUART, FL--(Marketwired - December 15, 2014) - Liberator Medical Holdings, Inc. (NYSE MKT: LBMH) today announced the financial results for its fiscal year ended September 30, 2014. Financial highlights are summarized below:

VIVUS Announces Favorable Formulary Positioning for Qsymia
MOUNTAIN VIEW, CA--(Marketwired - December 15, 2014) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today announced that Qsymia is the sole anti-obesity agent listed on the CVS/Caremark Performance Drug List, or PDL

Experts Say Parents Play a Key Role in Childhood Tooth Decay Prevention
WASHINGTON, DC--(Marketwired - December 12, 2014) - By mid-afternoon, Heather Hereford is exhausted. With a set of twins and a son all under the age of 4, running on four hours of sleep isn't unusual.

Biodel to Report Fourth Quarter Fiscal Year 2014 Financial Results on December 17, 2014
DANBURY, CT--(Marketwired - December 10, 2014) - Biodel Inc. (NASDAQ: BIOD) will issue its fourth quarter fiscal year 2014 financial results on Wednesday, December 17, 2014. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.

Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that the U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for BTI-320 to treat Type 2 diabetes and weight management

New Management of Biostem Technologies (BSEM) Announces Name and Symbol Change to Be in Effect Today; BSEM Also Moves Forward to Complete an Interactive Webpage and Will Be Attending the 22nd Annual World Congress on Anti-Aging Medicine Dec 11-13, 2014
OAKLAND PARK, FL--(Marketwired - December 09, 2014) - Biostem Technologies, Inc. (OTC PINK: BSEM) (BSEM), is pleased to announce the Financial Industry Regulatory Agency (FINRA) has approved a name and symbol change from Caribbean International Holdings, Inc. to Biostem Technologies, Inc. (BSEM) effective today. The new management believes this name will reflect Biostem Technologies, Inc

Omni Bio Announces Encouraging Clinical Data for Use of Alpha-1 Antitrypsin (AAT) in Steroid-Resistant Graft Versus Host Disease
Omni Bio Pharmaceutical, Inc

Ossianix Expands and Extends Its Research Collaboration with Lundbeck on CNS Therapeutics
Ossianix, Inc. has announced an expansion and extension of its strategic research collaboration with H. Lundbeck A/S (Lundbeck). This collaboration follows a previous equity investment in 2012 and prior research collaboration in 2013

A New Era Comes When Diabetes Can Be Treated Basically Using Cells of Pancreas
STC Stem Cell Treatment & Research Institute (www.stcstri.com) of STC Life Co., Ltd. (Chairman: Kye Ho Lee) succeeded in differentiating new pluripotent stem cells without side effect into beta-cells that control insulin in pancreas, after conducting research projects for several years

Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Seattle Genetics, Inc

US Equity Holdings CEO Joins Buck Advisory Council
Chester Aldridge, Chairman and CEO of US Equity Holdings, has joined the Buck Institute's Buck Advisory Council (BAC). The long-time Marin resident will take an active role in advising the Institute on the commercialization of some of its most promising research assets

Niwali.com Launches Estrodetox
Can the use of marijuana cause man b**bs? According to an article Dr. Anthony Youn, a plastic surgeon from Detroit, wrote for CNN earlier this month, it can. The reason behind it is the drug's effect on hormone levels, causing an imbalance between testosterone and estrogen

Liberator Medical Reports Revenue of $69 Million for Its Fiscal Year Ended September 30, 2013
Liberator Medical Holdings, Inc. (NYSE MKT: LBMH) today announced the financial results for its fiscal year ended September 30, 2013. Financial highlights are summarized below:

Viridian Health Management Releases Year-End Wrap-Up of Product Launches, Initiatives, Leadership and Publications
PHOENIX, AZ--(Marketwired - December 20, 2013) - Viridian Health Management, a value-driven health improvement company focused on powering performance in population health, today released a year-end wrap-up and preview of activities for 2014.

Jafari Facebook Contest Brings Sugar-Free Dessert Recipes to Diabetics
Drawing on their deep knowledge and understanding of the challenges diabetics face when it comes to diet, Jafari Medical Supply recently sponsored a Facebook contest with the goal of collecting diabetic-friendly dessert recipes

Parks Associates: Networked Medical Devices to Exceed 14 Million Unit Sales in 2018
New digital health research from Parks Associates predicts U.S. unit sales of networked medical devices will exceed 14 million units by 2018, more than five times the sales from 2012

ANORO(TM) ELLIPTA(TM) Approved as First Once-Daily Dual Bronchodilator for the Treatment of COPD in the US
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc

Orgenesis Secures $3 Million in Funding From Kodiak Capital Group
Orgenesis, Inc. (OTCQB: ORGS), a development-stage company with a novel regenerative medicine technology that converts a diabetes patient's liver cells into functioning insulin-producing cells, has entered into a $3 million common stock purchase agreement with Kodiak Capital Group LLC, a Newport Beach, Calif.-based institutional investor.

Nuvilex's Medical Marijuana Research Could Use Cell Encapsulation Technology to Address Brain Cancers
The executives at Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., had to take note of recent results released in a marijuana study done by a group of researchers in Spain. The study used a type of encapsulation to inhibit brain cancer cell growth in mice

Letter to Islet Sciences, Inc. (ISLT) Shareholders From CEO James Green
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT)

It's Not Too Late to Vaccinate -- Get Your Flu Vaccine Today
WASHINGTON, DC--(Marketwired - December 10, 2013) - "Flu season typically peaks in February and can last as late as May," says Dr. Anne Schuchat, Assistant Surgeon General of the U.S. Public Health Service and Director of CDC's National Center for Immunization and Respiratory Diseases. "We are encouraging people who have not yet been vaccinated this season to get vaccinated now."

A Delicious Approach to Weight Loss, Healthy Eating
(Family Features) Weight loss tops the to-do list for many of us, especially at this time of year when thoughts turn to the holidays, resolutions, vacation and even the looming swimsuit season.

Insulet Announces Commercial Agreement With Amgen
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced an agreement with Amgen Inc., the world's leading independent biotechnology company, for a five year commercial agreement to supply Amgen with a delivery device specifically designed around the unique delivery needs of biotechnology medicines.

Metabolex Undergoes Capital Restructure and Renames as CymaBay Therapeutics
HAYWARD, CA--(Marketwired - December 10, 2013) - CymaBay Therapeutics, Inc., a biopharmaceutical company formerly known as Metabolex, has recently completed a capital restructuring. CymaBay will focus exclusively on advancing its clinical portfolio which consists of three compounds in Phase 2 clinical development that are designed to address unmet medical needs in the metabolic disease space

Boston Therapeutics Appoints Three to Management Positions
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, has appointed Edward Shea as Vice President Business Development, Tina M. Gagnon as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. as Clinical Affairs Manager, effective immediately.

GSK and Theravance Announce Positive Results From Pivotal Phase III Study for Fluticasone Furoate/Vilanterol in Asthma
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study of fluticasone furoate "FF"/vilanterol "VI" designed to support a potential filing for an asthma indication for adults in the US.

After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment
Eli Lilly & Co. (LLY) has parlayed its cancer drug Gemzar® or gemcitabine into well over $10 billion since it gained approval to treat advanced, inoperable pancreatic cancer back in 1996. Meanwhile, Nuvilex, Inc. (OTCQB: NVLX) has its eyes on a piece of that billion dollar pie with the company's live-cell encapsulation based treatment for pancreatic cancer

Historic 6th Annual Pharmaceutical Leadership Summit and Pharmaleaders Awards 2013 Focused to Give Aam Admi of India Affordable Medicines and Quality Healthcare
In a sequel to the sixty days of the voting by the Indian masses to select the best of the best in the final five nominees in various important categories & individual nonvoting categories, Pharmaleaders (www.pharmaleaders

Noted Healthcare Industry Experts and Medical Professionals to Receive Pharmaleaders 2013 Power Brand Awards
In an era where Healthcare in India is the most neglected as Politicians & Policy Makers are busy scoring their political points, Pharmaleaders attempt to raise the uncomfortable questions ignored by other media houses as we believe that healthcare is key to the nation development & India cannot be a mute spectator where policy reforms in healthcare has taken a backstage over political issues

Seattle Genetics and Takeda Highlight Long-term Follow-up Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Clinical Trials in Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma at ASH 2013
Seattle Genetics, Inc

ALR Technologies Announces Election of New Board Member and Appointment of Chief Commercial Officer
ALR Technologies Inc. (OTCBB: ALRT) (the "Company"), a health information technology developer, is pleased to announce the election of William S. Smith to the Board of Directors and the appointment of Mr. Smith as Chief Commercial Officer, effective January 1, reporting to CEO Sidney Chan. Mr

2013 Could Be "The Year of The Point of Care Test": Kalorama
A number of developments bode well for tests that are performed in the healthcare settings, according to Kalorama information. The healthcare market research publisher said that the nearly $17 billion point of care test (POCT) market will see faster revenue growth in 2013 than tests sent to central labs for processing

GoHealth: Affordable Care Act Changes in 2013
GoHealthInsurance, the leading online exchange for individuals and families to compare health insurance quotes, wants consumers to know how the Affordable Care Act (ACA) will affect health care in 2013. Americans will see important changes occur in health care programs and the way they can deduct medical expenses.

Western Diabetes Institute Shares Expertise in Response to Student's Death From Undiagnosed Diabetes
The tragic death of Fremont Academy of Engineering and Design 11th grade student Nikita Rodriguez from undiagnosed diabetes in late November 2012 was not in vain.

ActiveCare Announces Expansion of Customer Contract With Southern Benefit Services, LLC
ActiveCare, Inc. (OTCBB: ACAR), the service leader in disease and diabetes management, today reported the expansion of its customer contract with Southern Benefit Services, LLC. Through this contract, ActiveCare has added over 1,000 new members in the past 9 months with annualized revenues in excess of $1.2 million

Omni Bio Pharmaceutical Appoints New CEO
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr

Boston Therapeutics Approved in France to Initiate a Clinical Trial With SUGARDOWN(R) in Patients With Type II Diabetes
Boston Therapeutics, Inc

APMA and Neuropathy Action Foundation Team Up With Jerry Mathers to Raise Awareness
The American Podiatric Medical Association (APMA), the nation's leading professional organization for podiatrists, and Neuropathy Action Foundation (NAF), the premier patient advocacy organization for neuropathy education, have joined together to produce an educational video focusing on diabetic peripheral neuropathy featuring celebrity Jerry Mathers from the hit sitcom "Leave It to Beaver."

Medecision Awarded Full NCQA Disease Management Systems Certification
Medecision, the leader in collaborative healthcare management technology, today announced that it has earned National Committee for Quality Assurance (NCQA) Disease Management Systems Certification for the full suite of Aerial™ solutions including Disease Management (DM) Clinical Programs.

Poxel Raises €13 million to Progress Imeglimin Development to Treat Type 2 diabetes
Poxel S.A. /Poxel Raises €13 million to Progress Imeglimin Development to Treat Type 2 diabetes . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

How to Love Your Heart
(Family Features) It beats about 100,000 times a day, 35 million times a year. It pumps blood through the body three times every minute, taking that blood on the equivalent of a 12,000 mile trek every 24 hours. Even at rest, it works twice as hard as the leg muscles of a person running. The heart is a remarkable, vital muscle that warrants great care and maintenance

GCS-100 Demonstrates Statistically Significant Reduction in Liver Fibrosis
La Jolla Pharmaceutical Company (OTCQB: LJPC) (the "Company" and "La Jolla"), a leader in the development of therapeutics that target galectin-3, announced today the results of a mouse study examining the effect of GCS-100 on liver fibrosis

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
Novartis International AG /Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Eye Health and Vision Care Should Be Essential Covered Services Offered by Health Plans
Americans would benefit from having all health plans cover vision exams as part of their standard benefit according to a new study in the Archives of Ophthalmology, published December 10, 2012

Next-Generation OmniPod(R) Insulin Pump Cleared by FDA
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology, today announced that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next-generation OmniPod® Insulin Management System

eMarketer Expands Coverage of Industry Verticals
eMarketer announced today that it will significantly expand its coverage of several major verticals to meet growing demand from eMarketer clients focused on those industries.

VisualMED and Intelaform Expand Partnership to Address Hospital Readmission Reduction Transition Care Programs in National Capital Region
VisualMED Clinical Solutions Corp. ("VisualMED") (PINKSHEETS: VMCS) (FRANKFURT: VA6) and Intelaform, Inc. ("Intelaform") announce an expansion of their Maryland transitional care initiative to include the District of Columbia by forming the National Capital Region Hospital Readmission Reduction Consortium ("NCR Consortium")

New Quintiles Resource for Cancer Patients Wins Third Health Award for ClinicalResearch.com
Cancer patients looking for clinical trials of oncology therapies in their own areas plus information and news to help them understand the disease and its treatments have a valuable new online resource at www.ClinicalResearch.com. The Quintiles-created site has now been recognized with its third Web Health Award in as many years.

Heartbeat Experts Expands Pharmaceutical Clients in Emerging Markets
Heartbeat Experts, the global leader in stakeholder management solutions for the life sciences industry, announced today increased revenue and expanded clients across Brazil, Russia, China, India and Korea. Heartbeat Experts’ reported combined revenue from these markets grew 50% in the third quarter of 2012.

Pathway Genomics Partners with Medcan Clinic, the Largest Private Health Care Clinic in Canada
Pathway Genomics Corporation, a San Diego-based clinical laboratory that offers clinical genetic testing services internationally, has partnered with the Medcan Clinic, Canada’s largest private health care clinic.

Regarding meat as 'treat' may help tackle obesity
One should only eat meat on feast days to help tackle obesity, a government food advisor has advised.

3 cups of black tea a day can cut heart attack risk by 60pc
Drinking just three cups of black tea a day can slash the risk of a heart attack by 60 per cent and dramatically reduce the threat of diabetes, experts say.

1 in 5 elderly people overindulging in alcohol
Boredom and loneliness in the post retirement phase is paving way for more and more older people to binge on alcohol beyond recommended levels, a new study has revealed.

ARI Recognized as an American Heart Association Platinum-Level Start! Fit-Friendly Company
ARI®, a leading global vehicle fleet management provider specializing in complex car and truck fleet programs, has been recognized as a Platinum-Level Start! Fit-Friendly Company by the American Heart Association's Start! initiative for helping employees eat better and engage in more physical activities.

Holman Automotive Recognized by American Heart Association as Worksite Fitness Innovation Company of 2011
Holman Automotive Group, one of the nation's top auto dealership and leasing companies, has been recognized by the American Heart Association as one of two Worksite Fitness Innovation Companies of 2011. The Biannual award is given to companies that develop and implement innovative and effective programs to promote physical activity in the workplace

Pacific Biomarkers Announces the Appointment of Amar A. Sethi, MD, PhD as Its New Chief Scientific Officer
Pacific Biomarkers (PBI), a Seattle, WA-based limited liability company that provides premier biomarker and specialty efficacy testing services to the drug development industry, has named the company's current Vice President, Research and Development, Amar A. Sethi, MD, PhD, as the new Chief Scientific Officer effective January 1, 2012. Dr

Boston Therapeutics Elects Dr. Henry Esber to Its Board of Directors
Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the election of Dr. Henry J. Esber to its Board of Directors, effective December 20, 2011.

Sugar free strawberries cultivated in Uttarakhand
Farmers in Ramnagar in Uttarakhand's Nainital District have taken up sugar free strawberry cultivation with an aim to ensure that the patients suffering from diabetes are able to consume it.

Brain cell malfunction linked to schizophrenia
Defect in certain portions of protein that package DNA is the root cause of Schizophrenia and the deficit is especially pronounced in younger people, a new study has suggested.

Is poor diet of shift workers a new form of occupational hazard?
The poor diet of shift workers should be considered as a new occupational health hazard, a new study has claimed.

Comment on this story

Share